Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Associated Therapies: -

Clinical Trials

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Phase 2

Terminated

Conditions: Refractory Malignant Peripheral Nerve Sheath Tumor
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Neuroblastoma
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Desmoplastic Small Round Cell Tumor
Recurrent Malignant Peripheral Nerve Sheath Tumor
Refractory Desmoplastic Small Round Cell Tumor
Recurrent Desmoplastic Small Round Cell Tumor
Recurrent Malignant Solid Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Etoposide
Drug: Fludarabine Phosphate
Biological: Lapine T-Lymphocyte Immune Globulin
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2020-08-28

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04530487

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Phase 2

Withdrawn

Conditions: Hematologic Malignancy
Hematologic Diseases
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia

Interventions: Device: CliniMACS
Procedure: Bone Marrow Transplant
Drug: Hyperfractionated Total Body Irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-02-24

Last Posted Date: 2022-09-27

Lead Sponsor: Baptist Health South Florida

Registration Number: NCT04282174

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukaemia
High-risk Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cytarabine
Drug: Vyxeos
Drug: Busulphan
Drug: Thiotepa

First Posted Date: 2020-01-03

Last Posted Date: 2023-05-10

Lead Sponsor: University of Birmingham

Target Recruit Count: 333

Registration Number: NCT04217278

Locations: 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧
Manchester Royal Infirmary, Manchester, United Kingdom

and more 11 locations

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes

Interventions: Drug: CD8+ Memory T Cell Infusion
Drug: Thiotepa
Drug: Fludarabine
Radiation: Hyperfractionated TBI
Drug: Busulfan
Drug: Cyclophosphamide

First Posted Date: 2019-11-05

Last Posted Date: 2024-10-17

Lead Sponsor: Robert Lowsky

Target Recruit Count: 7

Registration Number: NCT04151706

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Phase 2

Terminated

Conditions: Acute Megakaryoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Acute Erythroid Leukemia
Myelodysplastic Syndrome With Excess Blasts
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation
Biological: Dilanubicel

First Posted Date: 2019-09-10

Last Posted Date: 2024-06-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04083170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Cleveland Cord Blood Center, Cleveland, Ohio, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Phase 2

Recruiting

Conditions: Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Interventions: Drug: Thiotepa
Drug: Treosulfan
Drug: Fludarabine Phosphate
Biological: Rabbit Anti-Thymocyte Globulin
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection

First Posted Date: 2019-06-10

Last Posted Date: 2024-07-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03980769

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

First Posted Date: 2019-05-31

Last Posted Date: 2024-08-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03970096

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Phase 1

Completed

Conditions: Hematological Malignancy
Acute Leukemia in Remission
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndromes
Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Interventions: Biological: Cord blood stem cells
Drug: Valproic Acid
Drug: Fludarabine
Drug: cytoxan
Drug: Thiotepa
Biological: TBI

First Posted Date: 2019-03-22

Last Posted Date: 2021-05-24

Lead Sponsor: Alla Keyzner

Target Recruit Count: 7

Registration Number: NCT03885947

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy